Suppr超能文献

拉米夫定对乳腺癌化疗所致乙型肝炎病毒再激活的预防作用:一项Meta分析

Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.

作者信息

Tang Wei, Chen Lun, Zheng Ruohui, Pan Lingxiao, Gao Jin, Ye Xigang, Zhang Xiaoshen, Zheng Wenbo

机构信息

Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, People's Republic of China.

Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, People's Republic of China; Department of Biotechnology, School of Life Science, Sun Yat-sen University, Guangzhou, 510275, People's Republic of China.

出版信息

PLoS One. 2015 Jun 9;10(6):e0128673. doi: 10.1371/journal.pone.0128673. eCollection 2015.

Abstract

BACKGROUND

Three strategies using lamivudine have been proposed to prevent chemotherapy-induced HBV (hepatitis B virus) reactivation in the clinical setting. The purpose of this meta-analysis is to evaluate the efficacy of the early preemptive strategy, deferred preemptive strategy and therapeutic strategy in patients with HBsAg-positive breast cancer during chemotherapy.

METHODS

Clinical studies published from database inception until Nov 1, 2014, were included for analysis. The primary outcomes were overall survival, rate of chemotherapy disruption and virological and clinical reactivation. The secondary outcomes were the rates of HBV-related chemotherapy disruption, HBV-related mortality, YMDD mutations and withdrawal hepatitis.

RESULTS

Four hundred and thirty patients in four studies that compared the early preemptive strategy with a therapeutic strategy were included. Application of early preemptive lamivudine was superior in reducing HBV recurrence (pooled OR: 0.12, 95% CI, 0.04 to 0.31, P< 0.0001), the incidence of HBV-related hepatitis (pooled OR: 0.13, 95% CI, 0.04 to 0.37, P< 0.0001) and the rate of chemotherapy disruption (pooled OR: 0.37, 95% CI, 0.23 to 0.60, P< 0.0001). In these two groups, no significant difference was found in overall mortality (P = 0.32), YMDD mutant rate (P = 0.13) or incidence of withdrawal hepatitis (P = 0.38). Of the two studies that compared the efficacy of an early and a deferred preemptive strategy, one showed that an early preemptive strategy significantly reduced the incidence of hepatitis (P = 0.046), whereas the other showed no significant difference (P = 0.7).

CONCLUSIONS

An early preemptive strategy is superior to a therapeutic strategy in decreasing the incidence of HBV reactivation, incidence of HBV-related hepatitis and rate of chemotherapy disruption in patients with breast cancer. A deferred preemptive strategy might be an alternative approach to controlling viral replication.

摘要

背景

在临床环境中,已提出三种使用拉米夫定的策略来预防化疗诱导的乙肝病毒(HBV)再激活。本荟萃分析的目的是评估早期先发制人策略、延迟先发制人策略和治疗策略在化疗期间对HBsAg阳性乳腺癌患者的疗效。

方法

纳入从数据库建立至2014年11月1日发表的临床研究进行分析。主要结局为总生存期、化疗中断率以及病毒学和临床再激活。次要结局为HBV相关化疗中断率、HBV相关死亡率、YMDD突变率和停药后肝炎发生率。

结果

四项比较早期先发制人策略与治疗策略的研究纳入了430例患者。应用早期先发制人拉米夫定在降低HBV复发率(合并OR:0.12,95%CI,0.04至0.31,P<0.0001)、HBV相关肝炎发生率(合并OR:0.13,95%CI,0.04至0.37,P<0.0001)和化疗中断率(合并OR:0.37,95%CI,0.23至0.60,P<0.0001)方面更具优势。在这两组中,总死亡率(P = 0.32)、YMDD突变率(P = 0.13)或停药后肝炎发生率(P = 0.38)未发现显著差异。在两项比较早期和延迟先发制人策略疗效的研究中,一项研究显示早期先发制人策略显著降低了肝炎发生率(P = 0.046),而另一项研究未显示显著差异(P = 0.7)。

结论

在降低HBV再激活发生率、HBV相关肝炎发生率以及乳腺癌患者化疗中断率方面,早期先发制人策略优于治疗策略。延迟先发制人策略可能是控制病毒复制的另一种方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b02/4461354/4b8e89e7b56b/pone.0128673.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验